01 January 2008
Pharmacokinetics of mycophenolic acid: A comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients
T. van GeldeAnn Transplant 2008; 13(1): 27-27 :: ID: 880181
Abstract
Mycophenolate mofetil (MMF) is widely used in the field of solid organ transplantation. In combination with calcineurin inhibitors it has become the most often used drug to prevent acute rejection. In an attempt to reduce the incidence of the gastrointestinal adverse events associated with MMF use, the enteric-coated mycophenolate sodium (EC-MPS) was developed. Unfortunately, in two clinical trials EC-MPS 720 mg twice daily and MMF 1000 mg twice daily showed similar efficacy and safety profiles. The two formulations are therefore considered to be therapeutically equivalent. MPA exposure, measured as the area under the plasma concentration time curve (AUC), does not differ during administration of bioequivalent dosages of the two drugs (720 mg EC-MPS and 1000 mg MMF). Also the pharmacodynamic effect, measured as inhibition of the target enzyme inosine monophosphate dehydrogenase (IMPDH) has been shown to be comparable between the two formulations. However, due to the enteric coating the pharmacokinetic profile of EC-MPS is different, with a longer and more variable time to reach the peak concentration (T[sub]max[/sub]). This increased variability in pharmacokinetics impacts on the application of therapeutic drug monitoring in patients using EC-MPS. It is well known that the correlation between pre-dose concentrations and AUC is poor for MMF. At the same time we also realize that drawing full AUCs, consisting of 8-12 blood samples over the 12-hour dosing interval, poses practical problems in routine clinical practice. Therefore limited sampling strategies have successfully been developed, in order to reliably estimate AUC, using only 2 or 3 samples obtained in the first few hours after oral MMF intake. Such limited sampling strategies however require reproducible pharmacokinetic profiles. In contrast to MMF the profiles obtained with EC-MPS show too much variability to develop reliable limited sampling strategies. This implies that the only method to reliably measure the MPA-AUC in a patient treated with EC-MPS is to perform a full (8-12 blood sample) AUC curve.
Keywords: Mycophenolate Mofetil, Organ Transplantation, plasma concentration
In Press
Case report
Pulmonary Embolism Following Living Donor Hepatectomy: A Report of 4 Cases and Literature ReviewAnn Transplant In Press; DOI: 10.12659/AOT.946752
Most Viewed Current Articles
03 Jan 2023 : Original article 6,527
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,222
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,152
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
17 Jan 2023 : Original article 5,279
Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation i...DOI :10.12659/AOT.938595
Ann Transplant 2023; 28:e938595